About this Research Topic
Cardiovascular diseases are a principal cause of death globally. Cardiovascular diseases include hypertension, atherosclerosis, ischemic heart disease, and heart failure which cause a hike in socioeconomic burden. The disorders can occur due to unhealthy lifestyle like smoking and high-fat diet, genetic, and age. Both experimental and clinical studies are in progress, in search for drugs with improved efficacy and lesser side effects. These studies and experimental research aim to develop novel cardiovascular drugs, many of which are used clinically to alleviate the symptoms and severity of the diseases. For instance, combined therapy of sacubitril/valsartan for patients with heart failure demonstrates better clinical outcomes than the use of valsartan alone. Moreover, recently, clinical indications of originally non-cardiovascular drugs such as sodium-glucose co-transporter-2 inhibitors (antidiabetic drugs) are repurposed for the treatment of cardiovascular diseases. Therefore, it is ultimately eminent for the research community to be updated with recent advances in cardiovascular pharmacotherapy.
Reviews in Cardiovascular Pharmacology: 2023 will publish high-quality scholarly review papers on key topics in Cardiovascular Pharmacology. It aims to highlight recent progress in the field, whilst emphasizing important directions and new possibilities for future inquiries. We anticipate the research presented will promote discussion in the Cardiovascular Pharmacology community that will translate to best practice applications in clinical, public health and policy settings.
The Reviews in Cardiovascular Pharmacology: 2023 collection welcomes full-length, mini or systematic review papers, but are not limited to articles that address recent development of molecular mechanisms, toxicology, or clinical aspects of pharmacotherapy of cardiovascular drugs, as well as potential candidates for cardiovascular drugs. Reviews on bioactive compounds from natural sources affecting cardiovascular are also welcomed. New articles will be added to this collection as they are published.
Reviews in Cardiovascular Pharmacology: 2023 will publish high-quality scholarly review papers on key topics in Cardiovascular Pharmacology. It aims to highlight recent progress in the field, whilst emphasizing important directions and new possibilities for future inquiries. We anticipate the research presented will promote discussion in the Cardiovascular Pharmacology community that will translate to best practice applications in clinical, public health and policy settings.
The Reviews in Cardiovascular Pharmacology: 2023 collection welcomes full-length, mini or systematic review papers, but are not limited to articles that address recent development of molecular mechanisms, toxicology, or clinical aspects of pharmacotherapy of cardiovascular drugs, as well as potential candidates for cardiovascular drugs. Reviews on bioactive compounds from natural sources affecting cardiovascular are also welcomed. New articles will be added to this collection as they are published.
Keywords: Cardiac, Heart, Blood Vessel, Myocardium, Vascular, #CollectionSeries
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
